{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-186437","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2025-08-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.686043+00:00","generated_at":"2026-05-17T10:31:31.871042+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"confidence":"high","headline":"Lyra Therapeutics receives Nasdaq deficiency notice for equity below $2.5M minimum","bullets":["Stockholders' equity as of June 30, 2025 was ~$1.6M, below the $2.5M continued listing requirement.","Company has 45 calendar days (until October 4, 2025) to submit a plan to regain compliance to Nasdaq.","If plan is accepted, Nasdaq may grant up to 180 additional calendar days to evidence compliance.","Failure to regain compliance could lead to delisting; Company may appeal to a Nasdaq Hearings Panel.","No immediate effect on listing or trading of common stock under symbol LYRA on Nasdaq Capital Market."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-186437","json":"https://secwatch.observer/filing/0001193125-25-186437.json","markdown":"https://secwatch.observer/filing/0001193125-25-186437.md","text":"https://secwatch.observer/filing/0001193125-25-186437.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000119312525186437/0001193125-25-186437-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000119312525186437/d931635d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T10:31:31.871042+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}